Widely published in scientific journals and with over 100 invited presentations, Caniggia also serves as a reviewer for a number of leading peer-reviewed scientific journals and has been the recipient of numerous academic honours, grants and awards, including a number from the respected Canadian Institute of Health Research (CIHR). Caniggia’s laboratory is at the forefront of research into the molecular signatures of preeclampsia and she is the inventor of Miraculins’ promising technology in this area.
“Dr. Caniggia’s dedication to reducing the suffering of women who develop preeclampsia, after her family was personally touched by this devastating disease, is deeply inspiring and I am very proud to have Isabella join our SAB”, said Christopher J. Moreau, president and chief executive officer of Miraculins. “Her leading research on hypoxic conditions of the placenta has advanced the field for early preeclampsia detection methods and includes the discovery of endoglin, which has consistently been the top performing biomarker for preeclampsia in a number of independent clinical studies.”
“I am pleased to join Miraculins in working towards the goal of better outcomes for women with preeclampsia and I am encouraged that our work will lead to improved early diagnostic tools so that physicians will no longer have to rely on symptoms alone to determine if a patient is at risk for developing preeclampsia”, commented Caniggia.